Immune-related adverse events of checkpoint inhibitors

Manuel Ramos-Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, Maria E. Suárez-Almazor

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or system. These effects are frequently low grade and are treatable and reversible; however, some adverse effects can be severe and lead to permanent disorders. Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short-term and long-term complications. Thoughtful management of irAEs is important in optimizing quality of life and long-term outcomes.

Original languageEnglish (US)
Article number38
JournalNature Reviews Disease Primers
Volume6
Issue number1
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Immune-related adverse events of checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this